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The relationship between sensitivity to antiviral drugs and viral fitness is of paramount importance in understanding the long-term
implications of clinical resistance. Here we report the development of a novel recombinant virus assay to study entry inhibitor-resistant HIV
variants using a biologically relevant cell type, primary CD4 T-cells. We have modified the replication-competent molecular clone HIVNL4-3
to express a reporter protein (Renilla luciferase), Green Fluorescent Protein (EGFP), or Red Fluorescent Protein (DsRed2) upon infection,
thus allowing quantification of replication. Luciferase-expressing virus was used to evaluate drug sensitivity, while co-infection with viruses
carrying the green and red fluorescent proteins was employed in the competitive fitness assay.
Using envelope proteins from three T20 insensitive variants, lower levels of resistance were observed in primary CD4 T-cells than had
been previously reported for cell lines. Importantly, dual-color competition assays demonstrated comparable or higher fitness for these
variants despite their reduced T20 sensitivity. We conclude that reduced sensitivity to T20 is compatible with high viral fitness in the absence
of selection pressure. Thus, simultaneously measuring both resistance and viral fitness using this newly described dual-color competition
assay will likely provide important information about resistant viral variants that emerge during therapy with entry inhibitors.
D 2005 Elsevier Inc. All rights reserved.
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The human immunodeficiency virus type 1 (HIV-1)
envelope glycoprotein (Env) consists of two subunits, the
outer surface unit (SU, gp120) and the transmembrane
protein (TM, gp41). Together, these glycoproteins mediate
virus entry into target cells. A detailed understanding of the
structural changes that take place in the envelope protein
during binding to CD4, coreceptor, and subsequently during
membrane fusion has created new opportunities to prevent0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.12.035
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Atlanta, GA 30329, USA.and treat HIV-1 infection. Recently, several compounds that
target different steps of viral entry have entered clinical
trials (for a review, see Clavel and Hance, 2004; Moore and
Doms, 2003; Pierson and Doms, 2003). So far, only the
fusion inhibitor T20 (also known as Enfuvirtide) which
targets gp41 has been approved for clinical use and is
currently included in combination antiretroviral treatment
strategies (Greenberg and Cammack, 2004).
The transmembrane protein gp41 is the fusogenic
component of the envelope/receptor complex. After tether-
ing the virus particle to the target cell through the fusion
peptide, conformational changes involving a membrane
distal hydrophobic region (HR2) and a more proximal
hydrophobic region (HR1) result in the formation of a six-
helix bundle and concomitant shortening of the molecule.
The change in free energy associated with this structural05) 251–262
T. Neumann et al. / Virology 333 (2005) 251–262252transition is considered to be sufficient to cause lipid mixing
and membrane fusion. Since the T20 peptide is based on the
sequence of the HR2 region from HIV-1LAI, it is predicted
to bind to a highly conserved hydrophobic groove located
on the trimeric coiled coils of HR1, thereby preventing the
formation of the six-helix bundle and inhibiting membrane
fusion (Moore and Doms, 2003; Pierson and Doms, 2003).
The clinical benefits of antiretroviral treatment are limited
by the selection of drug-resistant HIV-1 strains during
therapy (Clavel and Hance, 2004; Nunberg et al., 1991;
Richman, 1996). Databases of primary resistance mutations
that emerged in the presence of reverse transcriptase
inhibitor (RTI) and protease inhibitor (PI) therapy have been
useful in predicting clinical resistance based solely on
genotype. However, mutations in the reverse transcriptase
(RT) and protease (PR) genes that confer drug resistance
often also impair replication capacity (RC) (Blower et al.,
2001; Brenner et al., 2002). This notion is supported by the
observation that drug-susceptible variants rapidly outgrow
the drug-resistant viral quasispecies in vivo after discontin-
uation of treatment. In addition, several in vitro studies have
demonstrated a reduced overall performance of these
enzymes when substituted with primary resistance mutations
(Hance et al., 2001; Verhofstede et al., 1999). Secondary
mutations can enhance drug resistance, restore replication
capacity, or both. To determine viral fitness of drug-resistant
variants, phenotypic assays have been developed that
measure replication capacity in a single round infection
assay as well as in a spreading infection (Parkin et al., 2002,
2004; Petropoulos et al., 2000). In the case of replication-
competent viruses, parallel infections with different virus
variants are difficult to quantitate, especially when only
small differences are present and primary cells are used as
target (Domingo et al., 1997). In vitro competition between
two viruses (dual-infection/growth competition assay) using
relevant target cells (such as PBMC) is expected to more
accurately record relative fitness.
In vitro selection of T20-resistant HIV-1 variants by
Rimsky et al. (1998) demonstrated the importance of the
highly conserved, contiguous three amino acid residue
sequence GIV at position 36–38 within the first heptad
repeat region of gp41 (HR1) in the development of T20
resistance. Characterization of resistant viruses from phase II
trials revealed similar changes to those observed in tissue
culture, but indicated that the putative interaction site of T20
likely encompasses a larger region than previously consid-
ered, including residues 36–45 of HR1 (Poveda et al., 2002;
Xu et al., 2002). Moreover, regions in the gp120 surface
protein can also modulate sensitivity to T20 (Derdeyn et al.,
2000, 2001; Reeves et al., 2002). In addition to coreceptor
affinity, other steps within the entry process (attachment,
CD4-binding, and the kinetics of the conformational changes
within gp41) could also modulate the baseline susceptibility
to T20. Investigations using viruses derived from T20-naive
patients revealed a much wider range of T20 baseline
sensitivity compared to similar studies using reverse tran-scriptase (RT) or protease (PR) inhibitors (Derdeyn et al.,
2001; Hance et al., 2001; Labrosse et al., 2003; Verhofstede
et al., 1999). This wide range of T20 sensitivity makes it
difficult to define an absolute T20 therapy-induced resist-
ance threshold. Since different regions of the envelope
protein are likely to contribute to susceptibility to entry
inhibitors, it is also not feasible to predict resistance based on
viral genotyping alone. Therefore, the development of
phenotypic assays to assess entry inhibitor resistance and
viral fitness is of great importance. Our group and others
have demonstrated that recombinant virus assays (RVAs) can
be used for measuring phenotypic resistance (Dittmar et al.,
2001; Fikkert et al., 2002; Trouplin et al., 2001). However,
due to the complex interactions between distal regions of
Env, RVAs that incorporate the entire env gene of drug-naive
or T20-treated patients will be required to produce mean-
ingful data regarding resistance and fitness. Furthermore,
infection of T-cells most closely reflects the in vivo situation
and is therefore necessary to validate results obtained in cell
lines or indicator cells. To directly assess viral fitness of T20-
resistant virus relative to a sensitive strain, growth competi-
tion assays will be important (Lu and Kuritzkes, 2001;
Quinones-Mateu et al., 2000, 2002; Rangel et al., 2003).
These assays are beneficial in the context of evaluating
baseline virus from drug-naive patients, or after T20-treat-
ment failure to quantify the clinical benefit of this treatment
regimen. With regards to T20 treatment, a comprehensive
data set is slowly emerging. Recently, Lu et al. reported that
the viral fitness of HIVNL4-3 variants encoding T20 selected
point mutations in HR1 as well as full-length post-treatment
patient-derived envelope genes showed reduced fitness (Lu
et al., 2004). Nevertheless, more information between the
interplay of drug resistance and viral fitness is needed to
assess the long-term usefulness of fusion inhibitor therapy.
Here we analyzed envelope proteins from virus variants
with reduced T20 sensitivity obtained from three T20-naive
patients. We observed lower levels of resistance than had
been previously reported for the same variants analyzed in
cell lines. Importantly, dual-color competition assays
(DCCAs) with primary CD4 T-cells as targets demonstrated
comparable or higher fitness of these variants compared to a
coreceptor-matched subtype B reference virus. We conclude
that reduced sensitivity to T20 is compatible with high viral
fitness in the absence of drug selection pressure. By
measuring both drug sensitivity and viral fitness, the relative
cost of resistance to entry inhibitors can be better quantified.Results
Replication kinetics of the novel marker viruses are similar
to those observed for wild-type HIV-1NL4-3
One goal of this study was to establish a combined
resistance/viral fitness assay using primary T-cells as targets
to characterize Envs before therapy and during treatment
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recombinant marker viruses were constructed. The vectors
were designed for directional insertion of the env gene of
interest through use of two unique restriction sites present inFig. 1. (A) Schematic representation of the envelope-deleted marker virus plasmids
(TN7), EGFP (TN6G), and DsRed2 (TN6R) in the place of the nef gene. Insertio
was accomplished by restriction with BstEII and NcoI, resulting in full-length repl
and NL4.3Dnef in comparison to the marker viruses expressing the NL4-3 En
stimulated PBMC (C). Target cells were infected with an MOI = 0.001 and monit
genes (renilla luciferase, EGFP, DsRed2) are stable after serial passage on PM1 ce
p24 (detected using a fluorophore-conjugated anti-p24 antibody) to EGFP or DsR
transfection. To evaluate the stability of renilla luciferase expression (TN7-NL), th
virus and the ratio of (tat-induced) firefly to renilla luciferase activity was determthe env-deleted proviral constructs (Fig. 1A). We partially
removed the nef open reading frame and cloned the genes
for renilla luciferase, EGFP, and DsRed2 into a derivative of
the proviral clone pNL4-3 resulting in TN7D, TN6GD, andTN7, TN6G, and TN6R. These three plasmids encode for renilla luciferase
n of envelope genes from different patient samples after PCR amplification
ication competent proviral plasmids. (B and C) Growth of wild-type NL4.3
v (TN7-NL, TN6G-NL and TN6R-NL) in PM1 cells (B) and PHA/IL-2
ored over time for p24 antigen release into the supernatant. (D) The marker
lls. After three consecutive passages in PM1 cells, the ratio of intracellular
ed2 expression was compared to the original stock virus generated by 293T
e indicator cell line TZM-bl was infected with passaged and original stock
ined and compared.
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allow for the characterization of the envelope protein of
interest in terms of resistance and viral fitness compared to
standard or baseline HIV-1 envelopes in a primary T-cell
culture system.
We first investigated whether expression of the marker
genes (EGFP, DsRed2, and renilla luciferase) affected the
replication capacity of recombinant marker viruses express-
ing the env gene of NL4-3 in the T-cell line PM1 or in
primary T-cells. Infection of PM1 cells with the marker
viruses TN6G-NL and TN6R-NL resulted in replication
curves similar to that of wild-type and nef-deleted NL4-3
viruses (Fig. 1B). TN7-NL displayed a slight delay in
replication kinetics on PM1 cells, but this phenotype was
not observed in primary T-cells (Fig. 1C), where all three
marker viruses replicated with kinetics similar to the control
viruses.
To perform viral fitness assays, the marker viruses must
stably express the reporter genes over several rounds of
replication. Therefore, each reporter virus was serially
passaged three times on PM1 cells and reporter gene
expression of the passage 3 virus was compared to the
original stock (Fig. 1D).
In the case of TN6G-NL and TN6R-NL, the relative ratio
of viral protein expression and marker fluorescence intensity
was analyzed. Cells were fixed and stained for intracellular
expression of the HIV-1 capsid protein p24 using anti-p24
antibodies conjugated with phycoerythrin (for TN6G-NL) or
FITC (for TN6R-NL). Subsequently, cells were analyzed by
FACS and the ratio of cells expressing p24 and marker
protein was determined. Fig. 1D shows that this ratio was
very similar when infections with the transfection-derived
stock virus or with passage 3 virus were compared,
indicating that the marker gene was stably maintained. A
similar result was observed for TN7-NL. In this case, the
relative activity of firefly luciferase (induced by infection of
TZM-bl cells) and renilla luciferase activity (encoded by the
reporter virus) was quantified, and the ratio was shown to be
constant over 3 passages. All three reporter viruses thereforeTable 1
Amino acid sequence of heptad repeats 1 and 2 (HR-1 and HR-2) of the standard
A consensus_B sequence is included as reference (Con_B; residues in upper case
R14, X10, and X23 do not encode for residues in HR-1 known to confer T20 remaintain stable expression of EGFP, DsRed2, and renilla
luciferase after multiple passages in PM1 cells.
T20-insensitive envelope proteins expressed by the marker
virus TN7 display similar inhibition profiles on TZM-bl cells
and PBMC
It has been shown that entry inhibitor resistance can be
defined by infecting indicator cell lines, such as TZM-bl
(Wei et al., 2002) and CEM-NKR (Spenlehauer et al.,
2001), with viral isolates or Env pseudotypes. We therefore
determined the phenotypes of three previously characterized
T20-insensitive envelopes from three different patients (Heil
et al., 2004) using our luciferase reporter backbone TN7D
and the indicator cell line TZM-bl.
These env genes (R14, X10, and X23) were derived from
a large panel of isolates from T20-naive patients and are
representative of the wide range of T20 responsiveness that
has been described (Derdeyn et al., 2000, 2001; Labrosse et
al., 2003). The HR1 sequence of these Envs does not contain
amino acids in positions 36–45 that are known to confer T20
resistance, although the L45M variation in X10 has been
associated with T20 resistance when present in combination
with other mutations (Table 1). After inserting these three
envelope genes into TN7D, 293T cells were transfected and
recombinant virus harvested and titrated on TZM-bl cells.
Recombinant viruses encoding for renilla luciferase
(TN7) and expressing Envs from the X4-tropic virus NL4-
3 (NL) and the R5-tropic virus Yu2-(Yu2) were used for
comparison. Fig. 2A shows the inhibition of infection by the
five recombinant viruses in TZM-bl cells. Infection in the
absence of T20 was set to 100% and relative infection in the
presence of increasing concentrations of T20 is depicted.
This experiment demonstrated that viruses carrying the R14,
X10, and X23 Env required higher concentrations of T20
for inhibition than observed for the reference viruses (Fig.
2A). IC50 values were determined for all five viruses (Table
2) and the relative insensitivity was calculated. These results
confirmed the relative order of T20 insensitivity of theseviruses NL4.3 and Yu2 and the T20-insensitive viruses R14, X10, and X23
s are invariant in subtype B viruses). Note that the T20-insensitive viruses
sistance (location of resistance mutations are underlined for NL sequence).
Fig. 2. Sensitivity of patient-derived envelope proteins to the fusion inhibitor T20. The envelope genes R14, X10, and X23 were derived from T20-naive HIV-
positive individuals and have been described previously (Derdeyn et al., 2001; Heil et al., 2004). These envelope genes were cloned into TN7 and these viruses
were used to infect TZM-bl indicator cells (A) or PBMC (B). Reference viruses were constructed that express either the envelope of NL4-3 (TN7-NL) or Yu2
(TN7-Yu2). (A) TZM-bl cells were infected with 1000 IU/well in the presence of increasing concentrations of T20 (0.02–10 Ag/ml). Renilla luciferase activity
was measured 48 h post-infection and is plotted on the y-axis as the percent infection relative to control infection (without fusion inhibitor). These curves were
used to calculate IC50 values (see Table 2) for T20 for each envelope protein. Shown are the means of triplicate infections for each inhibitor concentration. (B)
CD8-depleted PBMCs were infected with 5000 IU/well using the concentrations of T20 described above. The percent infection relative to control infections
without fusion inhibitor is plotted against fusion inhibitor concentration. These data were used to calculate IC50 values for T20 for each envelope (see Table 2).
Shown are the means of triplicate infections for each inhibitor concentration.
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Envs confer a 7- to 14-fold lower sensitivity to T20 when
compared with the control viruses TN7-NL and TN7-Yu2.
These results were obtained through the detection of renilla
luciferase activity due to viral infection by the marker virus
TN7. The induction of firefly luciferase in TZM-bl cells
upon infection by these viruses resulted in similar inhibition
curves and changes in relative T20 insensitivity (data not
shown).
We next characterized the sensitivity to T20 upon
infection of primary T-cells (Fig. 2B). As described for
the TZM-bl experiments, primary T-cells were infected in
the presence of increasing concentrations of T20 and the
relative rate of infection was calculated from the renilla
luciferase activities obtained after 3 days. IC50 values for all
viruses tested were generally higher, including the controlTable 2
Evaluation of T20 sensitivity in TZM-bl indicator cells and PBMC relative
to reference strains
Env Coreceptor T20 IC50 (ng/ml) Relative T20
insensitivity
TZM-bl PBMC TZM-bl PBMC
NL X4 180 F 30 1500 F 80 1 1
Yu2 R5 200 F 20 800 F 55 1 1
R14 R5 1550 F 100 2000 F 50 7.5 2.5
X10 R5 2800 F 90 6500 F 50 14 8.1
X23 R5X4 1720 F 110 3200 F 120 9 2.0–4.0
The mean IC50 values of the TN7 vector expressing envelope proteins NL,
Yu2, R14, X10, and X23 were calculated from at least four independent
TZM-bl and PBMC infections. Coreceptor usage for the T20-insensitive
Envs was determined using GHOST indicator cells (data not shown) and is
indicated in the second column. Relative T20 sensitivity was calculated by
dividing the IC50 value for each T20-insensitive Env by the IC50 value for
TN7-NL or TN7-Yu2, respectively (depending on coreceptor usage).
Accordingly, the dual-tropic envelope X23 has been attributed two values.viruses (IC50 between 800ng/ml to 6500ng/ml) in compar-
ison to the data obtained from TZM-bl infections. Impor-
tantly, the relative order of resistance was preserved, but the
relative differences were much less pronounced. This is best
seen when looking at the fold change (Table 2), which
ranges from 7.5- to 14-fold in TZM-bl cells and from 2.5- to
8-fold in primary T-cells.
Dual-color competition assay in PM1 cells and PBMC
Reduced viral fitness contributes to the continued benefit
of antiviral therapy despite the presence of drug resistance.
In the case of reverse transcriptase and protease inhibitors,
drug resistance is associated with a reduction in viral fitness
(Quinones-Mateu et al., 2002; Rangel et al., 2003).
To establish dproof of conceptT for the dual-color
competition assay, PM1 cells were infected (MOI = 0.025)
with marker viruses encoding for the wild-type NL4-3
envelope protein and an envelope protein encoding a single
amino acid change at position 38 of gp41 (V38A: GIA),
known to confer resistance to T20 in vitro and in vivo. Cells
were harvested at day 3 and day 7 post-infection with
TN6G-NL and TN6R-GIA and total EGFP and DsRed2
fluorescence (at 508 nm and 582 nm, respectively) was
determined using a fluorometer. Fig. 3 illustrates one
example of the viral fitness data obtained. Since the ratio
of green fluorescence to red fluorescence changed between
day 3 and day 7 for both marker viruses (e.g., TN6G-NL/
TN6R-NL and TN6G-GIA/TN6R-GIA), a neutral zone was
defined for each experiment and each time point (grey area
in Fig. 3, see also Figs. 4B and C). A difference in viral
fitness was only considered valid if both time points
revealed a growth advantage for one envelope variant over
the other. The dual infection of PM1 cells with the two
Fig. 3. Relative fitness of TN6G and TN6R marker viruses expressing the
reference envelope NL compared to GIA, an envelope protein encoding for
a single point mutation at position 38 (V38A: GIA), known to confer
resistance to T20 in vitro and in vivo. A dual infection/growth competition
assay was performed on PM1 cells. PM1 cells were infected at an MOI of
0.025 with competing viruses expressing EGFP or DsRed2. Representative
results are shown. The dneutralT zone is shown in grey. Only EGFP/DsRed2
fluorescence ratios calculated above or below this dneutralT zone are
considered as the EGFP virus having a growth advantage over the DsRed2
virus or vice versa. In addition, the EGFP/DsRed2 fluorescence ratio must
remain above the neutral zone at both time points (day 3 and day 7) for the
EGFP expressing virus to be considered as having a true growth advantage
over the DsRed2 expressing virus. These results were confirmed by
switching the marker genes between a certain pair of viruses and the ratio
(DsRed2 vs. EGFP) for both days falling into the dredT zone.
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green to red fluorescence ratio of 50 at day 3 and 35 at day
7, significantly outside the dneutral zoneT (ratio between 8
and 20), indicating a growth advantage of TN6G-NL. The
opposite pair of viruses was analyzed as well (TN6G-GIA
and TN6R-NL), and resulted in green to red fluorescence
ratios of 3 and 4 for day 3 and day 7 post-infection. These
ratios were again outside the defined dneutral zoneT.
Therefore, both combinations of envelope genes were tested
and for both dual-color competition assays the recombinant
virus encoding the wild-type envelope protein of NL4-3
scored as dmore fitT compared to the recombinant virus
encoding the T20-resistant envelope protein GIA, confirm-
ing results by Lu et al. (2004).
Next, a potential correlation between T20 baseline
insensitivity and viral fitness was analyzed. To this end,
the dual-color competition assays were performed in
primary T-cells using the EGFP and DsRed2 marker viruses
expressing T20-insensitive Envs or reference Envs. This
provided a direct comparison of viral fitness relative to the
more sensitive NL4-3 and Yu2 recombinant viruses in a
more relevant primary cell system.
Initially, viral input and the time course of fitness
measurement were optimized for the dual-color competition
assay in PBMC. It had been shown that high viral input
results in dually infected cells (Dang et al., 2004) and such
cells are the source for recombination. Therefore, PBMCs
were infected at a low infectious dose of virus (MOI =
0.001, titrated on PBMC) to minimize the potential for
recombination between the two viruses investigated. Thisinfectious dose resulted in 5–15% infected cells on day 4
and 10–25% infected cells on day 8 (depending on the
donor PBMC) with no double-positive cells detected by
FACS analysis. These two time points were chosen for
fitness measurements because sufficient cell numbers were
detectable on day 4 and increasing numbers of dead cells
were apparent at time points later than day 8.
Fig. 4A illustrates an example of the viral fitness data
obtained. The dual infection of PBMC with TN6G-X10
and TN6R-X10 (gX10/rX10) resulted in a green fluores-
cence to red fluorescence ratio of 3.5 at day 4 and 2.8 at
day 8. The dual infection using TN6G-X10 and TN6R-NL
(gX10/rNL), however, resulted in a fluorescence ratio of
3.5 at day 4 and increased to 8.5 at day 8, indicating a
growth advantage of the recombinant virus encoding the
X10 Env. This result was confirmed by the dual infection
using the reverse pair of marker-protein-expressing viruses.
The dual infection using TN6G-NL and TN6R-X10 (gNL/
rX10) resulted in a fluorescent ratio of 0.2 for day 4 and
day 8, indicating a growth advantage of the marker virus
TN6R-X10. Again, the ratio of green fluorescent to red
fluorescent cells changed between day 4 and day 8 for
marker viruses expressing the same env gene (e.g., TN6G-
X10/TN6R-X10 and TN6G-NL/TN6R-NL), therefore a
neutral zone was defined for each FACS-based experiment
and each time point (grey area in Figs. 4B and C) as well.
A difference in viral fitness was only considered valid if
both time points revealed a growth advantage for one
envelope variant over the other (boxed pairs in Figs. 4B
and C). In addition, due to differences in the maturation
time between EGFP and DsRed2, and the residual green
fluorescence of the mature DsRed2 protein, both combi-
nations of envelope genes were tested and scored positive
only if both combinations yielded the same results (Fig.
4A for envelope protein X10).
All possible combinations were tested in this assay and
significant differences were observed for viruses carrying
the X10 env gene against the respective reference viruses.
For both time points, the dgreenT marker virus expressing the
X10 envelope was more fit compared to TN6R-NL, the
DsRed2 expressing control virus. Infections using the
reverse pair of marker viruses and envelope proteins
revealed again that TN6R-X10 was more fit than TN6G-
NL (Fig. 4). Similar results were obtained when the dual
infections were carried out using marker viruses expressing
X10 envelope and Yu2 envelope, respectively (Fig. 4C).
Surprisingly, the X10 envelope carrying marker virus
efficiently out-competed viruses carrying either the NL4-3
or the Yu2 envelope proteins, although these are inhibited
by concentrations of T20 that are 4-fold and 8-fold less than
for X10 env carrying recombinant viruses. The other T20-
insensitive envelopes, R14 and X23, were similar in fitness
compared to the control viruses expressing NL4-3 and Yu2
envelopes (Figs. 4B and C) when expressed by the novel
color marker viruses despite their 2-fold greater resistance
against T20.
Fig. 4. Relative fitness of TN6G and TN6R marker viruses expressing the reference envelopes NL and Yu2 compared to patient-derived envelopes R14, X10,
and X23. A dual infection/growth competition assay was performed on CD8-depleted PBMC. PBMCs were infected at an MOI of 0.001 with competing
viruses expressing EGFP or DsRed2. (A) Percentage of fluorescent cells was measured at day 4 and day 8 post-infection with TN6G-X10/TN6R-X10, TN6G-
X10/TN6R-NL, and TN6G-NL/TN6R-X10, respectively. The ratio of EGFP to DsRed2 (FL1/FL2) was determined at both time points. (B and C) A dual
infection/growth competition assay was performed on CD8-depleted PBMC. PBMCs were infected at an MOI of 0.001 of competing virus pairs expressing
EGFP or DsRed2. Representative results from two independent infections of PBMC (done in triplicate) are shown. These infections resulted in 5–15% infected
cells at day 4 and 10–25% infected cells at day 8. The dneutralT zone is shown in grey. Only EGFP/DsRed2 ratios calculated above this dneutralT zone are
considered as the EGFP virus having a growth advantage over the DsRed2 virus. In addition, the EGFP/DsRed2 ratio must remain above the neutral zone at
both time points (day 4 and day 8) for the EGFP-expressing virus to be considered as having a true growth advantage over the DsRed2-expressing virus. These
results were confirmed by switching the marker genes between a certain pair of viruses and the ratio (DsRed2 vs. EGFP) for both days falling into the dredT
zone. The boxed pairs for B and C indicate the pairs with the highest relative fitness score observed.
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shown, we calculated the relative fitness of each marker
virus encoding for the different envelope proteins in
relation to the standard viruses encoding for the
envelope proteins NL and Yu2, respectively (Table 3).
This resulted in the establishment of an order of viral
fitness for the envelope expressing marker viruses that
were studied:
R14 ¼ Yu2 b NL4:3 ¼ X23 b X10Discussion
Here we describe novel marker viruses that can be used
for quantification of entry inhibitor resistance in conjunction
with true viral fitness measurements using a dual-color
competition assay (DCCA). Furthermore, these parameters
can be evaluated using biologically relevant target cells such
as primary CD4 T-cells, rather than indicator cells or T cell
lines as described before (Dittmar et al., 2001; Fikkert et al.,
2002; Lu and Kuritzkes, 2001; Spenlehauer et al., 2001;
Table 3
Relative fitness of recombinant viruses carrying T20-insensitive Envs
Relative fitness (RF)
Relative to NL Relative to Yu2
NL 1.0 1.4 F 0.1
Yu2 0.7 F 0.2 1.0
R14 n.d. 0.9 F 0.1
X10 2.5 F 0.3 3.0 F 0.4
X23 1.8 F 0.3 1.2 F 0.1
The dual infection/growth competition assay was used to compare the
relative fitness of each patient-derived Env to NL4-3 (X10 and X23) or Yu2
(R14, X10, X23). The relative viral fitness was calculated as fold difference
between the ratio of green to red fluorescence (FL1/FL2 ratio) of a given
envelope variant and the mean FL1/FL2 ratio of the neutral zone at day 8
post-infection (see Figs. 3B and C). The relative fitness was calculated from
four independent experiments (n.d. = not done).
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nef gene for either the renilla luciferase gene or one of the
two fluorescent proteins, EGFP and DsRed2, respectively,
resulted in replication-competent viruses that had replication
kinetics comparable to both wild type and nef-deleted NL4-3
(Figs. 1B and C). This result was a critical prerequisite to
establish the dual infection/growth competition assay. A
second prerequisite was that the marker gene be stably
expressed over multiple rounds of replication. All three
marker genes were stably expressed after three passages in
PM-1 cells (Fig. 1D). Finally, the detection of all three
marker genes requires limited sample preparation (renilla
luciferase: lysis of cells and transfer to a luminometer; EGFP
and DsRed2: fixation of cells and transfer to FACScan or
fluorometer) and all measurements can be performed with
high throughput. Thus, this reporter virus system is well
suited to study the links between entry inhibitor resistance
and viral fitness, allowing quantitative luciferase activity
measurements in primary T-cells as well as efficient and
quantitative measurement of viral spread in dually infected
cultures using FACS or fluorometer analysis.
Several envelope-deleted marker viruses that could be
used to study viral sensitivity to entry inhibitors have been
described (Connor et al., 1995; He et al., 1997). Our
intention was to develop a system in which viral fitness
could be directly compared with sensitivity to entry
inhibitors. Here we inserted three patient-derived env genes
from viruses with varying levels of T20 and T649 sensitivity
into each of the three marker viruses to simultaneously
assess T20 sensitivity and viral fitness relative to a reference
virus. IC50 values similar to those previously described
(Derdeyn et al., 2001; Heil et al., 2004) were obtained for
each recombinant virus (Table 2). Higher IC50 values were
obtained in PBMC compared to cell lines, which is
consistent with some previous studies (Ketas et al., 2003),
but not others (Derdeyn et al., 2000, 2001). However, drug
sensitivity assays using both TZM-bl and PBMC as target
cells resulted in the same order of sensitivity to T20, with
X10 envelope carrying recombinant virus being the least
sensitive. Importantly, the estimated fold change (FC) orrelative T20 insensitivity for the recombinant viruses
carrying T20-insensitive envelopes relative to the reference
viruses was smaller on PBMC than on TZM-bl indicator
cells. This result indicates a potential overestimation of
emerging entry inhibitor resistance when cell lines are used.
However, greater numbers of pre-treatment and resistant
envelope proteins expressed by the recombinant marker
viruses need to be studied to clarify this finding.
The dual-color competition assay on PM1 cells using
EGFP and DsRed2 expressing recombinant viruses encoding
for wild type NL4-3 envelope and the known T20 resistant
envelope GIA (Fig. 3) confirmed previous data regarding the
reduced viral fitness of the GIA variant (Lu et al., 2004).
Furthermore, this result provided proof of concept for this
fluorescence-based assay to yield meaningful data. The dual-
color competition assay on primary T-cells described here in
detail resulted in the determination of a relative viral fitness
order for three recombinant viruses carrying T20-insensitive
envelope proteins (R14, X10, X23) in comparison to two
reference viruses (NL4-3, Yu2). Many assays to determine
replication capacity have used cell lines rather than primary
cells (Prado et al., 2002; Resch et al., 2002; Simon et al.,
2003; Trkola et al., 2003; Zhang et al., 2004). In the case of
protease inhibitors (PI), it has been shown that the
metabolism and/or export of PIs from the cytoplasm differ
between T cell lines and primary T-cells (Kim, 2003). These
observations argue that more biologically relevant systems,
such as the PBMC-based viral fitness assay described here,
will be useful in studying entry inhibitor resistance and its
consequences on viral fitness. However, one has to keep in
mind that all recombinant virus assays analyze the phenotype
of RT, protease, or the envelope protein after cloning the
respective genes into modified marker virus plasmids. The
interaction of patient-derived envelope protein and patient-
derived gag, for example, cannot be addressed and might
contribute to viral fitness as well.
Reference envelope proteins, such as the well-charac-
terized envelope proteins of NL4-3 and Yu2, are useful to
facilitate the validation and comparison of data generated
from different studies. In the present study, the recombinant
virus carrying the X10 envelope gene has the greatest level
of relative fitness, although this envelope confers the most
insensitive T20 phenotype, with an IC50 8-fold higher than
that required to inhibit NL4-3 on PBMC. The other two
T20-insensitive envelope proteins R14 and X23 cloned into
the marker viruses did not show a substantial growth
advantage over the reference viruses NL4-3 and Yu2, but
did not show a reduction in fitness either. Interestingly, the
X23 Env confers a 70-fold less sensitive phenotype on
TZM-bl cells to a related fusion inhibitor, T649, compared
to NL4-3 (Heil et al., 2004), yet these two recombinant
viruses exhibit a similar level of viral fitness. In the present
study, an inverse correlation between fusion inhibitor
insensitivity and viral fitness was not observed.
For the fusion inhibitor T20, our results indicate that the
envelope protein can accommodate baseline insensitivity,
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reduction in replication fitness. Such variants with consid-
erable primary insensitivity against T20 (i) may contain a
rather low genetic barrier for T20-induced resistance at least
in some patients or (ii) may be able compensate T20
treatment-induced loss of viral fitness. Highly insensitive
Envs from naive patients could therefore contribute to the
selection of T20-resistant variants without a significant
fitness cost. This has been shown for RTI and PI selected
variants (Nijhuis et al., 2001), where secondary mutations
compensated for a reduction in fitness. Therefore, additional
experiments using T20-resistant envelope proteins obtained
from long-term-treated patients (likely to have developed
secondary mutations) are needed to clarify whether com-
pensatory mutations are detectable and can restore fitness
once T20 resistance has developed.
However, clinical trials revealed that growth of T20-
resistant virus was impaired (Greenberg and Cammack,
2004). Recently, Lu et al. determined the fitness of HIVNL4-3
variants encoding for T20 selected amino acid residues in
HR1 found in treated patients. Using a growth competition
assay, they confirmed a reduced viral fitness of such
recombinant point mutation bearing viruses as observed in
clinical trials as did recombinant viruses encoding for full-
length, post-treatment envelope genes (Lu et al., 2004).
Thus, T20-induced resistance development certainly has an
effect on HIV-1 fitness as observed for other therapeutic
strategies (Nijhuis et al., 2001). For further studies, pre-
treatment samples from the same patient shall be used as
reference envelopes (Simon et al., 2003) resulting in the
most accurate assessment of fitness of HIV variants
emerging over time as the result of effective T20 therapy.
Taken together, we have established a novel marker virus
system that facilitates simultaneous assessment of viral
fitness and entry inhibitor sensitivity using biologically
relevant primary T-cells as targets. For T20-insensitive
envelope proteins from treatment-naive patients, an inverse
correlation between fusion inhibitor insensitivity and viral
fitness was not observed. The efficient characterization of
large numbers of Envs from pre- and post-treatment samples
and quantitative analysis using multiple marker proteins will
greatly enhance our understanding of the interplay between
resistance and fitness. This system can also be used to
compare escape from neutralizing antibody vs. fitness,
which is important for understanding the consequences of
neutralization escape.Materials and methods
Plasmid construction
We previously described the plasmid clone pNL-DK
(Dittmar et al., 2001) which was used in recombinant virus
assays to determine coreceptor usage of primary envelopes
cloned from HIV-positive individuals. To improve thissystem, the nef gene was replaced by one of three marker
genes (Renilla luciferase, EGFP, or DsRed2) to create
proviral derivatives that express one of the three reporter
proteins (designated TN7D, TN6GD, and TN6RD, respec-
tively). We chose renilla over firefly luciferase due to its
smaller gene size. To facilitate directional cloning of patient-
derived env genes, two unique restriction sites were
introduced into these vectors. Both modifications, a BstEII
site (position 90 of the env gene) and an NcoI site (one
nucleotide after the stop codon of the env gene, coinciding
with the start codon of the marker genes) have been
described previously (Polzer et al., 2001; Welker et al.,
1998) (Fig. 1A). Here, we utilized the BstEII–NcoI sites to
clone and express different envelope genes amplified using
PCR primers modified from Gao et al. (1998). Viruses
expressing the well characterized NL4.3 (CXCR4-tropic, or
X4) and Yu2 (CCR5-tropic, or R5) Envs were compared
with those derived from three T20-naive individuals (R14,
X10, and X23) (Derdeyn et al., 2001; Heil et al., 2004).
Isolate X10 was previously shown to be the most T-20-
insensitive virus from a panel of 55 primary isolates, and
isolate X23 was the most insensitive to a related peptide
inhibitor T-649, whereas R14 was unusual in its insensitivity
to both inhibitors (Derdeyn et al., 2001). All env genes were
cloned into each of the proviral clones.
Production and titration of virus stocks
To generate infectious virus stocks, 293T cells (1  106
cells) were transfected with 6 Ag DNA and 15 Al Fugene6
(Roche, Germany) according to the manufacturer’s instruc-
tions. Virus containing supernatant was harvested 3 days
later and after filtration stored at 80 8C. For some
experiments, the supernatant was concentrated 10-fold
using Millipore filter devices to increase the titer. Virus
stocks were titrated using the indicator cells TZM-bl which
were seeded at a density of 3  103 cells per well in a 96-
well tray. The next day, 5-fold dilutions of 293T-derived
virus stocks were used to infect TZM-bl cells and 48 h
later the cells were fixed with 3% paraformaldehyde and
stained by the addition of 5-bromo-4-chloro-3-indolyl-h-
galactopyranoside (X-Gal; 0.5 mg/ml in phosphate-buf-
fered saline (PBS) containing 3 mM potassium ferricya-
nide, 3 mM potassium ferrocyanide, and 1 mM magnesium
chloride) (Wei et al., 2002). Individual groups of blue-
stained cells were counted as single foci of infection and
virus infectivity was determined as focus forming units.
Titration on CD8-depleted PBMC (see below) was
performed using a limiting dilution strategy with 5 
104 cells per well in a 96-well tray and analyzed by a p24-
ELISA 7 days post-infection.
Growth curve analysis and marker gene stability
Growth curve analysis was performed using either the
T-cell line PM1, a subclone of HuT78 expressing CD4,
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depleted PBMC. PBMCs from HIV-seronegative individ-
uals were purified by the Ficoll-Hypaque method and
depleted of CD8-positive T-cells using anti-CD8 mag-
netic bead-conjugated antibodies (Miltenyi, Germany).
After stimulation with 0.5 Ag/ml phytohemagglutinin A
(PHA, Sigma, Germany) for 48 h, the cells were
maintained in RPMI 1640 with 20% fetal calf serum
(FCS), 20 U/ml recombinant human IL-2 (Roche,
Germany), and antibiotics. Using equal amounts of
infectious particles (TN7-NL, TN6G-NL and TN6R-
NL), 1  106 stimulated donor PBMC or PM1 cells
were infected (MOI of 0.001). After adsorption at 37 8C
for 4 h, the cells were washed three times with PBS and
observed for p24-CA production in the supernatant over
time using an in house ELISA assay (Dittmar et al.,
2001).
In order to evaluate the long-term stability of the
marker gene, PM1 cells were infected successively at an
MOI of 0.001 with each of the marker viruses expressing
the NL4-3 envelope gene (TN7-NL, TN6G-NL and TN6R-
NL) separately. Briefly, for the first passage, virus
containing supernatant was harvested at 10 days post-
infection and titrated on PM1 cells. A second passage was
then initiated using the same MOI and virus harvested at
day 10 post-infection. After the third consecutive passage,
infected cells were fixed and permeabilized and the
expression of EGFP and DsRed2 was evaluated in relation
to intracellular p24 expression using PE- and FITC-
conjugated anti-p24 antibodies (Coulter, Germany), respec-
tively. In the case of TN7-NL, virus produced from the
third passage was analyzed by comparing the expression of
firefly luciferase induced in TZM-bl cells upon infection to
expression of renilla luciferase due to virus infection (see
Fig. 1C).
T20 inhibition studies with TZM-bl and PBMC
For the T20 inhibition studies on TZM-bl cells, equal
amounts of infectious particles (1000 IU/well of TN7
derived infectious viruses) were added per well in the
absence or presence of 10, 2, 0.4, 0.08, and 0.004 Ag of
T20/ml. Triplicate wells were analyzed for each drug
concentration. For the T20 inhibition studies on PBMC,
equal amounts of infectious particles (5000 IU/well of
TN7 derived infectious viruses) were added per 1  105
PBMC in a round bottom 96-well tray in the absence or
presence of 10, 2, 0.4, 0.08, and 0.004 Ag of T20/ml.
Each drug concentration was analyzed in triplicate. For
both TZM-bl and PBMC, the cells were lysed at 2 days
post-infection and the renilla luciferase activity (expressed
due to infection with TN7 derived viruses) was measured
using the renilla activity assay (Promega, Germany) and a
luminometer (Labsystems, Germany). Relative activity
(percentage of control) was calculated by dividing the
mean number of relative light units at each T20concentration by the mean number of relative light units
from wells containing no drug.
Dual-color competition assay
The fitness of recombinant viruses carrying different
env genes was determined by simultaneous infection with
two viral species (e.g., TN6G-NL and TN6R-X10) at an
MOI of 0.001 (determined using PBMC) in triplicate on
6-well plates. Each well contained 1  106 CD8-depleted
PBMC in 1 ml RPMI medium. After 6-h adsorption at
37 8C, the cells were washed once in medium to remove
residual input virus. To determine the relative replication
capacity of one virus over the other, half of the cells
were harvested 4 days post-infection, fixed with 3%
paraformaldehyde, and analyzed by FACScan to measure
the percentage of cells expressing EGFP (TN6G-derived
viruses) or DsRed2 (TN6R-derived viruses) using the
appropriate channels FL1 and FL2, respectively. The
same analysis was performed with the remaining cells 8
days post-infection to confirm the first data set and to
evaluate the growth advantage. All growth competition
assays were performed at least three times independently
in triplicate with PBMC isolated from different donors.
Infection with two marker viruses expressing the same
envelope (e.g., TN6G-NL and TN6R-NL) was included
in each competition experiment for standardization. The
results of all growth competition experiments were
confirmed by expressing the opposite Env-reporter gene
combination. The ratio of the number of EGFP-positive
cells in channel FL1 vs. the number of DsRed2-positive
cells in channel FL2 at day 4 and day 8 was measured to
quantitate the growth difference for the respective
recombinant virus pair. Similarly, the dual-color competi-
tion assay on PM1 cells was performed. PM1 cells were
dually infected (MOI = 0.025 as determined using TZM-
bl cells) with TN6G-NL and TN6R-GIA or the opposite
virus pair. Cells were fixed 3 days post-infection and 7
days post-infection, and total EGFP fluorescence (508
nm) and DsRed2 fluorescence (582 nm) were determined
using a multiwell fluorometer. The ratio of EGFP
fluorescence vs. DsRed2 fluorescence correlates to the
growth difference for the respective recombinant virus
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